Reporter brief
Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract provides no results, effect sizes, or efficacy data—only the study protocol and rationale
- The pilot design and lack of a control group mean no causal conclusion about sirolimus efficacy can be drawn
- The study's findings on safety and any vision preservation outcomes are not reported here
Study design and sample
Other; Human.
People with geographic atrophy (GA) in both eyes with visual acuity between 20/20 and 20/400 in each eye; women of childbearing potential are eligible (implied by pregnancy testing)
- Design
- Other
- Sample
- —
- Journal
- National Eye Institute (NEI)
- Published
- Jul 14, 2020
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.